Osteoporosis therapies for rheumatoid arthritis patients: Minimizing gastrointestinal side effects

Seminars in Arthritis and Rheumatism

Volumn 30, Issue 4, 2001, Pages 288-297

  Sewell, Kathryn ^a   Schein, Jeffrey R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alendronate; Gastrointestinal side effects; Nonsteroidal anti inflammatory drugs; Osteoporosis; Rheumatoid arthritis

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CORTICOSTEROID; ESTROGEN; NONSTEROID ANTIINFLAMMATORY AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

DISEASE ACTIVITY; DISEASE PREDISPOSITION; ESOPHAGITIS; ESTROGEN THERAPY; GASTROINTESTINAL SYMPTOM; HUMAN; MEDICAL DECISION MAKING; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0035101417     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1053/sarh.2001.16648     Document Type: Article

References (94)

1. Extra-articular manifestations of rheumatoid arthritis: Risk factors for serious gastrointestinal events
2. Sacral insufficiency fractures in rheumatoid arthritis
3. Osteoporosis in rheumatoid arthritis: Effect of disease activity
4. The prevention and treatment of osteoporosis
5. Prevention and treatment of osteoporosis: Does the future belong to hormone replacement therapy?
6. Current and potential future drug treatments for osteoporosis
7. Should we look for osteoporosis in patients with rheumatoid arthritis?
8. Alendronate: A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis
9. Glucocorticoid-induced osteoporosis: Pathogenesis and management
10. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
11. Corticosteroid-induced osteoporosis
12. Glucocorticoid-induced osteoporosis: Pathogenesis, prevention and treatment, with special regard to the rheumatic diseases
13. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration
14. Contrasting presentation and findings between patients with rheumatic complaints taking nonsteroidal anti-inflammatory drugs and a general population referred for endoscopy
15. The gastroenterologist's caseload: Contribution of the rheumatologist
16. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury
17. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis
18. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs
19. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease
20. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs
21. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs
22. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: A prospective observational cohort study
23. Corticosteroid use and peptic ulcer disease: Role of nonsteroidal anti-inflammatory drugs
24. Impact of NSAID choice and patient symptoms on the cost effectiveness of strategies to prevent NSAID gastropathy
25. Mechanisms of action of anti-inflammatory medications used for the treatment of osteoarthritis
26. Celecoxib
27. Risk factors for serious nonsteroidal-induced gastrointestinal complications: Regression analysis of the MUCOSA trial
28. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: A randomized, double-blind, placebo-controlled trial
29. Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models
30. Osteoporosis: Detection, prevention, and treatment in primary care
31. Treatment of postmenopausal osteoporosis
32. AUK Consensus Group on management of glucocorticoid-induced osteoporosis: An update
33. Designing clinical trials of treatment for osteoporosis: Recruitment and follow-up
34. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
35. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
36. Effects of alendronate on gastric and duodenal mucosa
37. Cyclical clodronate is effective in preventing postmenopausal bone loss: A comparative study with transcutaneous hormone replacement therapy
38. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss
39. Cyclical intravenous clodronate in postmenopausal osteoporosis: Results of a long-term clinical trial
40. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis
41. The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons
42. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
43. Bisphosphonates: Preclinical aspects and use in osteoporosis
44. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts
45. Nonclinical model for assessing gastric effects of bisphosphonates
46. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
47. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy
48. A tale of two worlds in prescribing etidronate for osteoporosis
49. A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone
50. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone
51. Comparative study of potential for bisphosphonates to damage gastric mucosa of rats
52. Bisphosphonates: Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease
53. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling
54. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis
55. Prevention of nonvertebral fractures by alendronate: A meta-analysis
56. Treatment of osteoporosis with bisphosphonates
57. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients
58. Alendronate-induced ulcerative esophagitis
59. Esophageal ulceration due to alendronate
60. Esophageal stricture associated with alendronate therapy
61. Alendronate-induced esophagitis: Case report of a recently recognized form of severe esophagitis with esophageal stricture - Radiographic features
62. Multiple ulcerative esophagitis caused by alendronate
63. Esophagitis dissecans superficialis and alendronate: Case report
64. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis
65. Alendronate use among 812 women: Prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation
66. Incidence of gastrointestinal side effects due to alendronate is high in clinical practice
67. Evidence of estrogen receptors in normal human osteoblast-like cells
68. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
69. Focus on raloxifene: A selective estrogen receptor modulator for prevention of osteoporosis in postmenopausal women
70. Long-term estrogen replacement therapy prevents bone loss and fractures
71. Hip fracture and the use of estrogens in postmenopausal women: The Framingham study
72. Treatment of postmenopausal osteoporosis with transdermal estrogen
73. Bone response to termination of oestrogen treatment
74. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids
75. Effects of hormone replacement therapy in rheumatoid arthritis: A double blind placebo-controlled study
76. Intranasal salcatonin (salmon calcitonin): A review of its pharmacological properties and role in the management of postmenopausal osteoporosis
77. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: A prospective study
78. Calcitonin
79. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients
80. Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy?
81. Intranasal calcitonin for the prevention of bone erosion and bone loss in rheumatoid arthritis
82. Salmon calcitonin in the therapy of corticoid-induced osteoporosis
83. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: A two year follow up study
84. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis
85. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss
86. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis